SAS Output

18-JUN-2018 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1320-Adv, BRAF mut, Inter v Contin 1 Y 1 Lead-in Continuous Dosing 280 218 62 29 12 3 0 09/19/2014 229 106
            218 62 29 12 3 0      
 
    2 Y 2 Continuous Dosing 280 91 29 16 7 2 1 09/19/2014    
        3 Intermittent Dosing   87 25 14 8 1 0      
            178 54 30 15 3 1      
 
  S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 77 11 10 7 5 1 1 02/06/2017 75 39
            11 10 7 5 1 1      
 
  S1607-MELAN, Adv, T-VEC, MK-3475 1 Y 1 T-VEC + MK-3475(pembrolizumab) 64 1 1 1 1 1 0 06/05/2018   19
            1 1 1 1 1 0      
 
  S1616-MELAN, Adv, Ipilimumab Nivolumab 1 Y 1 Ipilimumab 94 4 4 3 2 1 0 10/23/2017   93
        2 Nivolumab + Ipilimumab   10 10 8 4 3 0      
            14 14 11 6 4 0      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   26 10 2 1 0 0 11/03/2015 346 147
            26 10 2 1 0 0      
 
    2 E Total Registrations   7 4 2 0 0 0 11/03/2015    
            7 4 2 0 0 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi Sargmostim 1 E Total Registrations   36 4 0 0 0 0 03/25/2016 301 120
            36 4 0 0 0 0